Response Genetics, Inc Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014
August 14, 2014 at 04:30 pm IST
Share
Response Genetics Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. Total revenue for the second quarter ended June 30, 2014 was $4.3 million compared to $3.9 million for the quarter ended March 31, 2014 and $5.3 million for the quarter ended June 30, 2013. The Company's net loss for the quarter ended June 30, 2014 was $3.1 million, or $0.08 per share, compared to a net loss of $3.5 million, or $0.09 per share, for the quarter ended March 31, 2014 and $1.3 million, or $0.04 per share, for the quarter ended June 30, 2013. Operating loss was $3,107,506 against $1,272,766 a year ago.
For the six months, net revenue was $8,176,169, operating loss was $6,585,375 and net loss was $6,643,411 or $0.17 per basic and diluted share against net revenue of $10,938,105, operating loss of $2,056,897 and net loss of $2,121,458 or $0.06 per basic and diluted share for the same period a year ago.
Response Genetics, Inc. is a life science company. The Company is engaged in the research, development, marketing and sale of pharmacogenomic tests for use in the treatment of cancer. To generate pharmacogenomic information from patient specimens for these tests, the Company uses its own methods for the extraction and analysis of nucleic acids and accessing the genetic information available from each patient sample. The Company's platforms include analysis of single biomarkers using the polymerase chain reaction method, as well as gene interrogation using microarray methods and fluorescence in situ hybridization (FISH) from paraffin or frozen tissue specimens. The Company is engaged in selling ResponseDX diagnostic testing products. The Company provides pharmacogenomic clinical trial testing services to pharmaceutical companies in the United States, Asia and Europe.
RESPONSE GENETICS, INC 
